[Arterial risk in type 2 diabetes: from mega-trials to prescription].
To oppose the increase in cardiovascular risk of diabetic patients several therapeutic options, validated in clinical trials, are available for the practitioner. However he is supposed to propose the most efficient combination. This strategy implies a reasonable estimation of the level of the cardiovascular absolute risk and of the risk/benefit ratio of the different options. The emerging challenge is to maintain a good observance despite the numerous and complex therapeutic associations given for life long.
Bonnet
Fabrice
F
Fédération d'endocrinologie-diabétologie, maladies métaboliques, nutrition Hôpital Cardiovasculaire 69394 Lyon.
Moulin
Philippe
P
D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control*; D002986:Clinical Trials as Topic; D003924:Diabetes Mellitus, Type 2 / Q000150:complications* / Q000188:drug therapy; D003925:Diabetic Angiopathies / Q000517:prevention & control*; D015438:Health Behavior; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D012307:Risk Factors
D007004:Hypoglycemic Agents; D010975:Platelet Aggregation Inhibitors